Events ESGCT

ESGCT

Celebrating the Progress of Advanced Therapies and Building the Future Through Translations

Oct 24 - Oct 27, 2023

Brussels, Belgium

Booth #86

Register for the conference

Every year, ESGCT hosts an Annual Congress where more than 100 world-renowned experts showcase their latest research. Whether they are Nobel Prize laureates or pioneers pushing the boundaries of the field, this event highlights the most current and groundbreaking research in gene and cell therapy.

Come visit us at booth #86 and discover MaxCyte's cGMP-compliant non-viral cell engineering platform and how it enables the acceleration of therapeutic development from concept to clinic.

While at the meeting, attend our feature presentation:

C57BL-D@2x

Featured Event

Next-generation CAR-based immunotherapies

Date: October 27
Time: 1:25 - 2:25 PM
Location: Shed 2B
Presenter: Prof. Michael Hudecek, MD

Abstract

Significant efforts have been invested in the development of advanced genetic engineering methods for immune effector cells targeting cancer cells. In this talk, optimized virus-free gene editing strategies for CAR T cells, refinement of clinical translation and the impact on their application will be presented. Insights into future directions to accelerate and amplify production to deliver CAR products with curative potential will be explored.

Presenter

230627_ukw_hudecek_dsc_8880

Prof. Michael Hudecek, MD, Professor of Cellular Immunotherapy, University of Würzburg

Prof. Michael Hudecek, MD, received his medical degree from the University of Leipzig, Germany. His doctoral thesis focused on the role of minor histocompatibility antigens in the graft-versus-leukemia response after allogeneic hematopoietic stem cell transplantation. He was then recruited to the Fred Hutchinson Cancer Research Center in Seattle, WA in 2007 to complete a postdoctoral fellowship in the laboratory of Stanley R. Riddell. In Seattle, he focused on the rational design of chimeric antigen receptors (CARs) and the definition of optimal cellular compositions of CAR-T cell products. Since 2012, he has been leading the translational CAR-T research program at the Department of Medicine II, University Hospital Würzburg, Germany. He has been appointed Associate Professor of Cellular Immunotherapy in 2020 and Full Professor of Cellular Immunotherapy in 2022 at the University of Würzburg. He was also a member of the Young Scholar Program and an extraordinary member of the Bavarian Academy of Sciences from 2015-2020, was awarded the Artur Pappenheim Prize of the German Society of Hematology and Medical Oncology in 2017 and the Friedrich Wilhelm Joseph von Schelling Prize of the Bavarian Academy of Sciences in 2022

Popular resources

Conditional-Deletion-of-Large-DNA-Fragment-in-iPSCs-by-ssODN-Mediated-Insertion-of-LoxP-Sites-without-Antibiotic-Selection-b 1
Scientific Brief
Conditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
Conditional-Deletion-of-Large-DNA-Fragment-in-iPSCs-by-ssODN-Mediated-Insertion-of-LoxP-Sites-without-Antibiotic-Selection-Fig-2 1
Scientific Brief
Gene Editing: Paving the Way for Accelerated Clinical Development of Adoptive Cell Therapies
Experimental-Design-hires 1
Scientific Brief
Conditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
View All Resources